ClinicalTrials.gg
Not yet recruitingNCT07704242Updated Jul 15, 2026

Early Kidney Injury Biomarkers in Gynecologic Laparoscopic Surgery

An observational study in Acute Kidney Injury and Subclinical Acute Kidney Injury, sponsored by Medipol University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Medipol University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 90 studies in Acute Kidney Injury with a site in Turkey — 21 open to participants now, 22 under way, none of them phase 3. Acute Kidney Injury · Turkey.

Planned enrollment
60th of 73
50 · median 130
Started
2026
with 17 others
Observational
73 of 90
15 open now
Primary completion
2027-02
later than 13 of 21 live
Registered
79th of 90
by date

Among the 90 studies in Acute Kidney Injury with a site in Turkey, this one is the 60th largest by planned enrollment of the 73 observational ones that give a count, is one of 18 that started in 2026, is one of 73 observational ones, reaches primary completion later than 13 of the 21 other live ones, and was the 79th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

21 of the 90 studies in Acute Kidney Injury with a site in Turkey are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies in Acute Kidney Injury with a site in Turkey, or all of them as a file.
02

Study summary

This prospective observational study aims to evaluate early subclinical acute kidney injury associated with pneumoperitoneum and Trendelenburg positioning during gynecological laparoscopic surgery. Urinary neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) levels will be measured and normalized to urinary creatinine. Biomarker changes will be compared between patients undergoing surgery in 30° and 45° Trendelenburg positions. The study seeks to determine whether these biomarkers can detect early renal injury before clinically significant changes in serum creatinine occur.

Read the detailed description

This single-center, prospective observational study aims to evaluate the effects of pneumoperitoneum and Trendelenburg positioning on early renal tubular injury during elective gynecological laparoscopic surgery. Although laparoscopic surgery provides well-established surgical benefits, carbon dioxide pneumoperitoneum combined with prolonged Trendelenburg positioning may reduce renal perfusion through alterations in intra-abdominal pressure and systemic hemodynamics. Conventional assessment of renal function relies primarily on serum creatinine, which may not increase until substantial nephron injury has occurred, limiting the early detection of subclinical acute kidney injury (AKI).

Adult patients scheduled for elective gynecological laparoscopic procedures with an anticipated operative duration of at least 90 minutes will be screened for eligibility. To minimize perioperative variability, anesthetic management, intraoperative fluid therapy, and perioperative care will be standardized for all participants according to the Enhanced Recovery After Surgery (ERAS) recommendations. Intra-abdominal pressure will be maintained within the routine clinical range of 12-14 mmHg throughout the procedure.

Participants will be allocated into two cohorts according to the Trendelenburg angle required for the planned surgical procedure: a 30° Trendelenburg group and a 45° Trendelenburg group. No intervention regarding patient positioning will be performed for study purposes, and group allocation will be based solely on routine surgical practice.

Urine samples will be collected at predefined time points: after induction of anesthesia and urinary catheterization (baseline) and at the sixth postoperative hour. Urinary neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) concentrations will be measured using enzyme-linked immunosorbent assay (ELISA). To reduce the influence of urine dilution and hydration status, biomarker concentrations will be normalized to urinary creatinine and expressed as NGAL/creatinine and KIM-1/creatinine ratios.

The study sample size was determined by power analysis, with a target enrollment of 50 participants. Statistical analyses will evaluate perioperative changes in urinary NGAL/creatinine and KIM-1/creatinine ratios between baseline and the postoperative period. Biomarker changes will be compared between the 30° and 45° Trendelenburg groups and analyzed in relation to the duration of pneumoperitoneum.

This study aims to determine whether perioperative changes in urinary NGAL and KIM-1 are associated with the degree of Trendelenburg positioning and the duration of pneumoperitoneum during gynecological laparoscopic surgery. The findings are expected to improve the understanding of early renal tubular stress associated with laparoscopic surgery and provide preliminary evidence for future studies investigating strategies to preserve renal function during minimally invasive surgical procedures.

03

Conditions studied

  • Acute Kidney Injury
  • Subclinical Acute Kidney Injury

Keywords

  • NGAL
  • KIM-1
  • Gynecologic Laparoscopy
  • Pneumoperitoneum
  • Trandelenburg Position
  • Acute Kidney Injury
  • Biomarker
  • Renal Injury
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of adult women undergoing elective gynecological laparoscopic surgery at a single tertiary care center. Eligible participants are those with an anticipated pneumoperitoneum duration of at least 90 minutes and a planned intraoperative Trendelenburg position of approximately 30° or 45°, according to routine surgical practice. Participants will be enrolled prospectively after providing written informed consent.

Eligibility criteria

Inclusion Criteria: Female participants aged 18 years or older. Scheduled for elective gynecological laparoscopic surgery. Expected duration of pneumoperitoneum of at least 90 minutes. Planned intraoperative Trendelenburg position of approximately 30° or 45°. Ability to provide written . -

Exclusion Criteria: Age younger than 18 years. Pre-existing chronic kidney disease (estimated \<60 mL/min/1.73 m² or serum creatinine above the institutional ).

Acute kidney injury before surgery. History of kidney transplantation or renal replacement therapy. Active urinary tract infection. Pregnancy. Conversion from laparoscopic to open surgery. Intraoperative conditions requiring major deviation from the standardized anesthetic or surgical protocol.

Inability to provide written informed consent.

-

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • 30° Trendelenburg Group

    Participants undergoing elective gynecological laparoscopic surgery requiring approximately 30° Trendelenburg positioning as part of routine surgical practice. Perioperative urinary NGAL, KIM-1, and urinary creatinine will be measured to evaluate changes in renal tubular injury biomarkers. Group allocation is based solely on the surgical positioning required for the planned procedure, with no study-related intervention.

    Procedure: Pneumoperitoneum and Trendelenburg Positioning

  • 45° Trendelenburg Group

    Participants undergoing elective gynecological laparoscopic surgery requiring approximately 45° Trendelenburg positioning as part of routine surgical practice. Perioperative urinary NGAL, KIM-1, and urinary creatinine will be measured to evaluate changes in renal tubular injury biomarkers. Group allocation is based solely on the surgical positioning required for the planned procedure, with no study-related intervention.

    Procedure: Pneumoperitoneum and Trendelenburg Positioning

Interventions

  • ProcedurePneumoperitoneum and Trendelenburg Positioning

    Standard intraoperative carbon dioxide pneumoperitoneum combined with either 30° or 45° Trendelenburg positioning during laparoscopic surgery

06

What researchers measure

Primary outcomes

  1. Perioperative Changes in Urinary Renal Tubular Injury Biomarkers

    Perioperative changes in urinary neutrophil gelatinase-associated lipocalin (NGAL)/creatinine and kidney injury molecule-1 (KIM-1)/creatinine ratios from baseline (after induction of anesthesia and urinary catheterization) to the sixth postoperative hour. Biomarker changes will be compared between participants undergoing surgery in approximately 30° and 45° Trendelenburg positions

    Time frame: Baseline (after induction of anesthesia and urinary catheterization) and postoperative 6 hours.

Secondary outcomes

  1. Association Between Urinary Biomarker Changes and Duration of Pneumoperitoneum

    Association between perioperative changes in urinary NGAL/creatinine and KIM-1/creatinine ratios and the total duration of pneumoperitoneum

    Time frame: From induction of anesthesia until completion of surgery, with biomarker assessment at baseline and postoperative 6 hours

  2. Comparison of Urinary Biomarker Changes According to Trendelenburg Position

    Comparison of perioperative changes in urinary NGAL/creatinine and KIM-1/creatinine ratios between the 30° and 45° Trendelenburg cohorts

    Time frame: Baseline (after induction of anesthesia and urinary catheterization) and postoperative 6 hours.

07

Study locations

1 site
  • Medipol Mega University Hospital
    Istanbul, Istanbul 34214, Turkey (Türkiye)
    • Isilay Ayar Gecginer, MD · Contactiayar@medipol.edu.tr · +902124607000
    • Isilay Ayar Gecginer, MD · Principal investigator
    • Ipek Keser Basbayandur, MD · Sub investigator
08

References and documents

Publications

  • Srisawat N, Kongwibulwut M, Laoveeravat P, Lumplertgul N, Chatkaew P, Saeyub P, Latthaprecha K, Peerapornratana S, Tiranathanagul K, Eiam-Ong S, Tungsanga K. The role of intraoperative parameters on predicting laparoscopic abdominal surgery associated acute kidney injury. BMC Nephrol. 2018 Oct 22;19(1):289. doi: 10.1186/s12882-018-1081-4. PubMed 30348111 ↗
  • Villa G, Fiorentino M, Cappellini E, Lassola S, De Rosa S. Renal implications of pneumoperitoneum in laparoscopic surgery: mechanisms, risk factors, and preventive strategies. Korean J Anesthesiol. 2024 Dec;77(6):575-586. doi: 10.4097/kja.24011. Epub 2024 Apr 26. PubMed 38664893 ↗
  • Kiseli M, Caglar GS, Yilmaz H, Gursoy AY, Candar T, Pabuccu EG, Bengisun ZK, Tuzuner F. Neutrophil Gelatinase-Associated Lipocalin Levels During Pneumoperitoneum. JSLS. 2017 Jan-Mar;21(1):e2016.00091. doi: 10.4293/JSLS.2016.00091. PubMed 28144124 ↗

Individual participant data

Plan to share: No — Individual participant data will not be made publicly available. Data were collected for the purposes of this investigator-initiated academic study and may contain information that could compromise participant confidentiality. Only aggregated study results will be reported in publications and presentations.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Feb 2027, 6 months later.

Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 6 months is below that.

Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2026
First posted
Jul 15, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07704242
Lead sponsor
Medipol University
Responsible party
Isilay Ayar Gecginer (Assistant Professor, Istanbul Medipol University Hospital) — Principal investigator
First posted
Jul 15, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Jul 15, 2026

Study contacts

Isilay Ayar Gecginer, MD
Contact
iayar@medipol.edu.tr
+902124607000 ext. 10233
Isilay Ayar Gecginer, MD
principal investigator · Istanbul Medipol University Faculty of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion